The use of pegulicianine fluorescence-guided surgery (pFGS) for identifying residual cancer in the tumor bed of patients undergoing breast-conserving surgery has an excellent safety profile and merits additional study, according to new research.
The findings were presented at the Society of Surgical Oncology 2022 International Conference on Surgical Cancer Care (abstract 20). The study showed fluorescence-guided surgery can be used to define tumor location and margins